Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data39
FAK inhibitors in cancer, a patent review – an update on progress38
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)38
Malaria transmission blocking compounds: a patent review36
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)35
Update on mGlu4 modulator patents: 2017 to present34
The role of patent analysis in target selection33
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)29
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities28
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)27
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review27
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present25
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)25
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)24
Caspase inhibitors: a review on recently patented compounds (2016–2023)23
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
An updated patent review of AKT inhibitors (2020 – present)22
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)21
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202320
Inhibition of GTPase KRAS G12D : a review of patent literature20
A patent review of MAPK inhibitors (2018 – present)20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)19
Antiprotozoal drugs: challenges and opportunities19
PDE1 inhibitors: a review of the recent patent literature (2008-present)18
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review18
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)15
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
An updated patent review of MALT1 inhibitors (2021–present)15
A patent review of IDH1 inhibitors (2018-present)15
Biofilm and bacterial membrane vesicles: recent advances14
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders14
Dopamine D3 receptor ligands: a patent review (2014–2020)14
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)14
Antimalarial drugs: what’s new in the patents?14
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
A patent and literature review of CDK12 inhibitors13
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Are patents important indicators of innovation for Chagas disease treatment?12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs12
An updated patent review on drugs for the treatment of tuberculosis (2018-present)12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)12
An updated patent review of EZH2 inhibitors (2024–present)12
A patent review of NLRP3 inhibitors to treat autoimmune diseases12
An updated patent review of TRPA1 antagonists (2020 – present)11
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience11
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents11
The patent review of the biological activity of tropane containing compounds11
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa10
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)10
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)10
Correction10
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)9
A patent review of BRD4 inhibitors (2020–present)9
Rho kinase inhibitors: a patent review (2017–2023)9
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published9
A patent review of CXCR7 modulators (2019-present)9
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)9
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)9
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)9
A patent review of selective CDK9 inhibitors in treating cancer9
Patent landscape of small molecule inhibitors of METTL3 (2020-present)8
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)8
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)8
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)8
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)8
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)8
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Therapeutic cysteine protease inhibitors: a patent review (2018–present)7
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)7
Nurr1 modulators – a patent review (2019–present)7
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20237
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid7
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update7
Recent advances in the development of STING inhibitors: an updated patent review7
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents7
A patent perspective of antiangiogenic agents7
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)7
Anticancer drugs: where are we now?6
An updated patent review of glutaminase inhibitors (2019–2022)6
An updated patent review on monoamine oxidase (MAO) inhibitors6
Pitfalls in patenting academic CAR-T cells therapy6
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)6
An updated patent review of stimulator of interferon genes agonists (2021 – present)6
An updated patent review of BRD4 degraders6
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)6
A patent review of xanthine oxidase inhibitors (2021–present)6
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)6
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)6
Proteasome inhibitors as anticancer agents6
A review of the patent literature surrounding TRPV1 modulators6
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)6
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective6
An updated patent review of Mcl-1 inhibitors (2020–2022)6
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)5
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
BET inhibitors: an updated patent review (2018–2021)5
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
A patent review of adenosine A2Breceptor antagonists (2016-present)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
Natural products as a source of new anticancer chemotypes5
CBL-B – An upcoming immune-oncology target5
A patent review of MLKL modulators (2023 – present)5
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)5
0.88274478912354